Zócalo Health, a provider of AI-powered virtual primary care for Latino patients, raised $15 million in Series A funding.
Including the latest Series A round, Zócalo Health has raised $22.75 million in funding to date. The startup secured a $5 million Seed round in September 2022, co-led by Animo Ventures, Virtue Ventures, and VamosVentures, with participation from Necessary Ventures and Able Partners, as well as angel investors Toyin Ajayi, Freada Kapor Klein, Nikhil Krishnan and Erik Ibarra.
Zócalo, which has headquarters in Kenmore, Washington, offers its virtual primary care services through one-time visit fees and membership dues. With fresh funds, Zócalo Health will accelerate nationwide expansion, scale its community-based workforce, and deepen partnerships with health plans.
Latinos are the largest minority group in the country. By 2050, they will make up more than 30% of the U.S. population, with 132.8 million people.
Despite the prevalence of Latinos across the country, the healthcare system still fails to meet the unique cultural needs of this population, Zócalo Health co-founder and CEO Erik Cardenas said in an interview with Medcity.
Zócalo Health partners with Medicaid managed care organizations, including Anthem Blue Cross and Health Net, to deliver services aligned with broader state-led initiatives such as CalAIM across California.
“We built Zócalo Health to consistently engage the patients the system misses,” said Erik Cardenas, Co-Founder and CEO. “Our model is designed around sustained engagement and outcomes. When you connect and engage RSS high-need members, you change both clinical outcomes and cost.”
Digital health companies, including telehealth, telemedicine, and virtual care startups, have secured more than $180 billion in funding to date, according to our recent Funding Database.
More recently, Click Therapeutics, a developer of AI-based digital therapeutics, raised $50 million in Series D funding from Boehringer Ingelheim.
In another deal, Remission Medical, a virtual rheumatology startup addressing a range of rheumatological conditions, including rheumatoid arthritis, osteoporosis, osteoarthritis, lupus, and gout, among others, raised a Series A funding round led by Blue Heron Capital.